Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.2740
+0.0030 (1.11%)
May 30, 2025, 4:00 PM - Market closed

Company Description

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.

It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.

The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.

It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Azitra, Inc.
Azitra logo
Country United States
Founded 2014
IPO Date Jun 16, 2023
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Francisco Salva

Contact Details

Address:
21 Business Park Drive
Branford, Connecticut 06405
United States
Phone 203 646 6446
Website azitrainc.com

Stock Details

Ticker Symbol AZTR
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001701478
CUSIP Number 05479L203
ISIN Number US05479L2034
Employer ID 46-4478536
SIC Code 2834

Key Executives

Name Position
Francisco D. Salva President, Chief Executive Officer and Director
Travis M. Whitfill M.P.H., Ph.D. Co-Founder, Chief Operating Officer, Secretary and Director
Norman Staskey Chief Financial Officer and Treasurer

Latest SEC Filings

Date Type Title
May 29, 2025 ARS Filing
May 29, 2025 DEF 14A Other definitive proxy statements
May 19, 2025 PRE 14A Other preliminary proxy statements
May 15, 2025 SCHEDULE 13G/A Filing
May 14, 2025 SCHEDULE 13G Filing
May 13, 2025 8-K Current Report
May 13, 2025 10-Q Quarterly Report
May 2, 2025 424B5 Filing
May 2, 2025 8-K Current Report
May 1, 2025 EFFECT Notice of Effectiveness